SAN DIEGO, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of iRhythm Technologies, Inc. (NASDAQ:IRTC) common stock between January 11, 2022 and May 30, 2023, inclusive (the "Class Period"), have until April 8, 2024 to seek appointment as lead plaintiff of the iRhythm class action lawsuit. Captioned Glazing Employers and Glaziers' Union Local #27 Pension and Retirement Fund v. iRhythm Technologies, Inc., No. 24-cv-00706 (N.D. Cal.), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm's top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the iRhythm class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-irhythm-technologies-inc-class-action-lawsuit-irtc.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
CASE ALLEGATIONS: iRhythm is a digital healthcare company that develops and manufactures heart monitoring devices designed to diagnose arrhythmias.
The iRhythm class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) iRhythm failed to comply with the U.S. Food and Drug Administration's ("FDA") marketing regulations and prohibitions against the promotion of products for uncleared and unapproved uses contrary to representations it made to investors; and (ii) iRhythm failed to report adverse events and other missed arrhythmic events to the FDA in violation of the reporting requirements of Medical Device Reporting regulations.
The iRhythm class action lawsuit further alleges that on November 1, 2022, iRhythm provided ...